Combination therapy with a compound acting as a platelet ADP receptor inhibitor
View Patent ↗The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.
1. A method for treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of the following therapeutic agents:
or a pharmaceutically acceptable salt thereof; and
(2) betrixaban or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the pharmaceutically acceptable salt of betrixaban is the maleate salt.
3. The method according to claim 1 , wherein at least one of the therapeutic agents is administered in a sub-therapeutic dosage.
4. The method according to claim 1 , wherein both of the therapeutic agents are administered in sub-therapeutic dosages.
5. The method according to claim 1 , wherein the two therapeutic agents are administered simultaneously.
6. The method according to claim 1 , wherein the two therapeutic agents are administered sequentially.
7. The method of claim 1 , comprising administering to said mammal a therapeutically effective amount of the following three therapeutic agents:
or a pharmaceutically acceptable salt thereof;
(2) an antiplatelet agent; and
(3) betrixaban or a pharmaceutically acceptable salt thereof.
8. The method according to claim 7 , wherein the pharmaceutically acceptable salt of betrixaban is the maleate salt.
9. The method according to claim 7 , wherein at least one of the therapeutic agents is administered in a sub-therapeutic dosage.
10. The method according to claim 7 , wherein all of the therapeutic agents are administered in sub-therapeutic dosages.
11. The method according to claim 7 , wherein the three therapeutic agents are administered simultaneously.
12. The method according to claim 7 , wherein the three therapeutic agents are administered sequentially.
13. The method according to claim 1 , wherein the pharmaceutically acceptable salt of
is the potassium salt or sodium salt.